New Neuropathological Staging System for Lewy Body Disease
Objective: Present the validation of the new proposed novel staging system (NSS) for Lewy body disease and compare it against the previously proposed staging systems. Background:…Identification and Characterization of Selective and High Affinity Small Molecules as Positron Emission Tomography (PET) Imaging Tracers for Pathological Alpha-Synuclein
Objective: The aim is to develop small molecular weight compounds which bind selectively and with high affinity to alpha-synuclein (a-syn) aggregates as diagnostic PET imaging…Fine-mapping of SNCA variants in REM sleep behavior disorder identifies distinct associations
Objective: a). Identify variants in the SNCA locus which affect risk for REM Sleep Behavior Disorder (RBD). b). Test variant effects on rate and type…Digital biomarker sensor feature data reflect quality of life judgements (PDQ39) in recently diagnosed Parkinson’s disease patients
Objective: To evaluate the extent to which data derived from smartphone-based testing and passive monitoring are related to what recently diagnosed Parkinson’s disease (PD) patients…Tau and amyloid-beta inclusions are present in pancreatic beta-cells of patients with synucleinopathies
Objective: We have assessed whether tau and amyloid beta deposits might be present in pancreatic tissue of subjects with Parkinson’s and Lewy Body dementia. Background:…Characterising the role of alpha-synuclein in ferroptotic programmed cell death in the context of Parkinson’s Disease
Objective: Despite the involvement of alpha synuclein (α-syn) pathology in Parkinson's disease (PD) pathology, the consequences on the neuropathology and the type of programmed cell…A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design
Objective: To evaluate the efficacy of the anti-alpha-synuclein monoclonal antibody PRX002/RG7935 in a proof-of-concept Phase 2 study in patients with early Parkinson’s disease (PD). Background:…A promising model for cognitive dysfunction in Parkinson’s Disease by AAV-mediated alpha-synuclein overexpression in hippocampus
Objective: Our aim is to model cognitive dysfunction of Parkinson's disease (PD) together with motor deficits by targeted overexpression of alpha-synuclein (a-syn) in bilateral dentate…Presence of Lewy dots in the brain of patients with Creutzfeldt-Jakob disease
Objective: We have investigated whether alpha-synuclein deposits exists in the brain of patients with Creutzfelt-Jakob disease Background: Creutzfeldt-Jakob’s disease (CJD) is a prion neurodegenerative disorder…Natural occurring antibodies reduce aggregation of α-synuclein
Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 60
- Next Page »